| 11/13/2026 4:08 PM | Alnylam Pharmaceuticals (1178670) Subject Capital Research Global Investors (1422848) Filed by | Form SCHEDULE 13G/A | |
| 11/13/2026 12:51 PM | Alnylam Pharmaceuticals (1178670) Subject Capital World Investors (1422849) Filed by | Form SCHEDULE 13G/A | |
| 11/12/2026 3:07 PM | Alnylam Pharmaceuticals (1178670) Issuer PYOTT DAVID E I (1051578) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/05/2026 12:10 PM | Alnylam Pharmaceuticals (1178670) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 11/05/2026 6:37 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/30/2026 12:36 PM | Alnylam Pharmaceuticals (1178670) Subject VANGUARD PORTFOLIO MANAGEMENT LLC (2100121) Filed by | Form SCHEDULE 13G | |
| 10/29/2026 7:16 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/29/2026 7:20 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/06/2026 3:12 PM | Alnylam Pharmaceuticals (1178670) Issuer SUPRAN BRYAN (1511797) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/02/2026 2:45 PM | Alnylam Pharmaceuticals (1178670) Subject SUPRAN BRYAN (1511797) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/22/2026 3:07 PM | Alnylam Pharmaceuticals (1178670) Issuer Greenstreet Yvonne (1446125) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for ALNY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/30/2026 7:11 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/30/2026 7:06 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/03/2026 3:21 PM | Alnylam Pharmaceuticals (1178670) Issuer Cravatt Benjamin (1819573) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 05/27/2026 3:30 PM | Alnylam Pharmaceuticals (1178670) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/22/2026 3:16 PM | Alnylam Pharmaceuticals (1178670) Issuer Reitan Colleen F (1740730) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/22/2026 3:18 PM | Alnylam Pharmaceuticals (1178670) Issuer SCHULMAN AMY W (1438226) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/22/2026 3:20 PM | Alnylam Pharmaceuticals (1178670) Issuer Sigal Charles Elliott (1661908) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/22/2026 3:04 PM | Alnylam Pharmaceuticals (1178670) Issuer Arbuckle Stuart A (1557290) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2026 3:17 PM | Alnylam Pharmaceuticals (1178670) Issuer SCHULMAN AMY W (1438226) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2026 12:55 PM | Alnylam Pharmaceuticals (1178670) Subject Capital World Investors (1422849) Filed by | Form SCHEDULE 13G/A | |
| 05/14/2026 9:19 AM | Alnylam Pharmaceuticals (1178670) Subject Capital Research Global Investors (1422848) Filed by | Form SCHEDULE 13G/A | |
| 05/06/2026 10:00 AM | Alnylam Pharmaceuticals (1178670) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 04/30/2026 7:04 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/30/2026 7:16 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 04/29/2026 3:44 PM | Alnylam Pharmaceuticals (1178670) Subject VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by | Form SCHEDULE 13G | |
| 04/07/2026 3:16 PM | Alnylam Pharmaceuticals (1178670) Issuer McLaughlin Melissa (2127187) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 04/07/2026 3:21 PM | Alnylam Pharmaceuticals (1178670) Issuer McLaughlin Melissa (2127187) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/06/2026 4:01 PM | Alnylam Pharmaceuticals (1178670) Filer | Form ARS | |
| 04/06/2026 3:30 PM | Alnylam Pharmaceuticals (1178670) Filer | Form DEF 14A | |
| 04/06/2026 3:31 PM | Alnylam Pharmaceuticals (1178670) Filer | Form DEFA14A | |
| 03/26/2026 2:24 PM | Alnylam Pharmaceuticals (1178670) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 03/06/2026 3:11 PM | Alnylam Pharmaceuticals (1178670) Issuer Fitzgerald Kevin Joseph (1886431) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/06/2026 3:12 PM | Alnylam Pharmaceuticals (1178670) Issuer Tanguler Tolga (1849458) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/06/2026 3:12 PM | Alnylam Pharmaceuticals (1178670) Issuer Poulton Jeffrey V. (1782962) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/06/2026 3:13 PM | Alnylam Pharmaceuticals (1178670) Issuer Greenstreet Yvonne (1446125) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/06/2026 3:13 PM | Alnylam Pharmaceuticals (1178670) Issuer Garg Pushkal (1829252) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 6:29 PM | Alnylam Pharmaceuticals (1178670) Issuer Greenstreet Yvonne (1446125) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 6:29 PM | Alnylam Pharmaceuticals (1178670) Issuer SUPRAN BRYAN (1511797) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 6:30 PM | Alnylam Pharmaceuticals (1178670) Issuer Tanguler Tolga (1849458) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 6:30 PM | Alnylam Pharmaceuticals (1178670) Issuer Fitzgerald Kevin Joseph (1886431) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
You missed yesterday's deadline… (Ad) In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years.
While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars. See which company controls this entire energy discovery now. |
| 03/04/2026 6:31 PM | Alnylam Pharmaceuticals (1178670) Issuer Garg Pushkal (1829252) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 6:31 PM | Alnylam Pharmaceuticals (1178670) Issuer Poulton Jeffrey V. (1782962) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/25/2026 3:17 PM | Alnylam Pharmaceuticals (1178670) Issuer Fitzgerald Kevin Joseph (1886431) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 6:26 PM | Alnylam Pharmaceuticals (1178670) Issuer Poulton Jeffrey V. (1782962) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 6:26 PM | Alnylam Pharmaceuticals (1178670) Issuer Fitzgerald Kevin Joseph (1886431) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 6:27 PM | Alnylam Pharmaceuticals (1178670) Issuer Tanguler Tolga (1849458) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 6:27 PM | Alnylam Pharmaceuticals (1178670) Issuer Greenstreet Yvonne (1446125) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 6:28 PM | Alnylam Pharmaceuticals (1178670) Issuer Garg Pushkal (1829252) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/12/2026 7:12 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/12/2026 7:05 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/14/2026 3:21 PM | Alnylam Pharmaceuticals (1178670) Issuer Fitzgerald Kevin Joseph (1886431) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/14/2026 3:22 PM | Alnylam Pharmaceuticals (1178670) Issuer Tanguler Tolga (1849458) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/14/2026 3:22 PM | Alnylam Pharmaceuticals (1178670) Issuer Poulton Jeffrey V. (1782962) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/14/2026 3:23 PM | Alnylam Pharmaceuticals (1178670) Issuer Greenstreet Yvonne (1446125) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/14/2026 3:23 PM | Alnylam Pharmaceuticals (1178670) Issuer Garg Pushkal (1829252) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/13/2026 3:32 PM | Alnylam Pharmaceuticals (1178670) Subject Fitzgerald Kevin Joseph (1886431) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/12/2026 6:30 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/07/2026 3:16 PM | Alnylam Pharmaceuticals (1178670) Issuer Arbuckle Stuart A (1557290) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 01/07/2026 3:17 PM | Alnylam Pharmaceuticals (1178670) Issuer Arbuckle Stuart A (1557290) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/11/2025 6:25 AM | Alnylam Pharmaceuticals (1178670) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/03/2025 3:49 PM | Alnylam Pharmaceuticals (1178670) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/19/2025 3:05 PM | Alnylam Pharmaceuticals (1178670) Issuer Fitzgerald Kevin Joseph (1886431) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 3:04 PM | Alnylam Pharmaceuticals (1178670) Subject Fitzgerald Kevin Joseph (1886431) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |